Argenx Announces Leadership Change with Karen Massey as Future CEO

Governance Changes to Be Approved by Shareholders

The governance changes announced by argenx SE will need to be approved by shareholders at the annual general meeting scheduled for May 6, 2026, the group stated. This several-month period is intended to allow a gradual transition of responsibilities. Tim Van Hauwermeiren will succeed Peter Verhaeghe as chairman of the board, who is retiring after serving on the board since 2008, the statement detailed. Karen Massey has been serving as the COO for the past three years at the Dutch company.

Focus on Long-Term Strategy and Board Evolution

In his new role as chairman, Tim Van Hauwermeiren will focus on long-term strategy and the evolution of the board, according to the statement. The co-founder of argenx stated that he will remain involved in the company's innovation mission by maintaining connections with the external ecosystem. According to the group, this transition is part of the preparation for the company's next phase of growth. Peter Verhaeghe, the outgoing chairman, emphasized that these changes come at an opportune time to support the biotechnology company's evolution towards its Vision 2030.

Karen Massey to Assume CEO Role Pending Shareholder Approval

Karen Massey, who will take over as CEO subject to shareholder approval, joined argenx three years ago, the statement recalled. During this time, she notably contributed to the launch of VYVGART, the first approved commercialized neonatal Fc receptor inhibitor by the group. Argenx develops and markets treatments for severe autoimmune diseases, leveraging its immunology innovation program aimed at translating scientific advances into antibody-based drugs. The company, listed on Euronext Brussels and the Nasdaq, is currently evaluating the potential of its portfolio in various autoimmune diseases, according to the statement.